News
Health Care Down After Eli Lilly Earnings -- Health Care Roundup
Shares of Eli Lilly plunged after the drug maker reported less-than-stellar results of a new study of an experimental anti-obesity pill that is expected to become a blockbuster. The pill helped people lose up to about 12% of their body weight after more than a year of treatment.
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...
The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
Good morning. Today, we read about the implications of mRNA funding cuts on national security, see layoffs at gene-editing ...
The iPhone maker's shares [rallied for a second day]( ...
Eli Lilly stock falls 14% after new obesity drug underwhelms in clinical trial. Analysts maintain Buy rating, citing strong ...
16hon MSN
Complaints pour in over Army Corps’ Los Angeles fire cleanup efforts Helicopter crashes into barge on Mississippi River near ...
Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback